ISO 3166-2:MD

D-BOX Technologies to Refile its MD&A for Fiscal Year Ended March 31, 2022 and its Financial Statements and MD&A for First Quarter of Fiscal 2023

Retrieved on: 
Thursday, August 18, 2022

D-BOX redefines and creates realistic, haptic and immersive entertainment experiences by providing feedback to the whole body and sparking the imagination through motion.

Key Points: 
  • D-BOX redefines and creates realistic, haptic and immersive entertainment experiences by providing feedback to the whole body and sparking the imagination through motion.
  • Haptic essentially allows to feel sensations that would be felt if the body was interacting directly with physical objects.
  • D-BOX has collaborated with some of the best companies in the world to deliver new ways to enhance great stories.
  • In particular, this release contains statements that may constitute forward-looking information relating to changes to, and refiling of, the MD&A for the fiscal year ended March 31, 2022 and the Q1 2023 Financial Reports.

mdf commerce reports First Quarter of Fiscal 2023 Financial Results

Retrieved on: 
Friday, August 12, 2022

Refer to the 11 - Non-IFRS Financial Measures and Key Performance Indicators section of the MD&A for the first quarter ended June 30, 2022.

Key Points: 
  • Refer to the 11 - Non-IFRS Financial Measures and Key Performance Indicators section of the MD&A for the first quarter ended June 30, 2022.
  • Refer to the 11 - Non-IFRS Financial Measures and Key Performance Indicators section of the MD&A for the first quarter ended June 30, 2022.
  • Refer to the 11 - Non-IFRS Financial Measures and Key Performance Indicators section of the MD&A for the first quarter ended June 30, 2022.
  • In this press release, mdf commerce, the Corporation or the words we, our and us refer, depending on the context, either to mdf commerce inc. or to mdf commerce inc. together with its subsidiaries and entities in which it has an economic interest.

Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

Retrieved on: 
Monday, December 13, 2021

Egis will sell Pliaglis through its own commercial infrastructure in CEE and Russia, where the company is well established.

Key Points: 
  • Egis will sell Pliaglis through its own commercial infrastructure in CEE and Russia, where the company is well established.
  • Crescita will be the exclusive supplier of Pliaglis at a defined price per unit and will also provide regulatory support to Egis in seeking approval for Pliaglis in the Territories.
  • Egis expects to launch Pliaglis in Poland in early 2023 and will submit the requisite regulatory filings as soon as practicable to ensure that Pliaglis is launched promptly in the other territories.
  • Pliaglis is a pivotal asset for Crescita and is key to helping unlock the long-term value of our company.